J.P. Morgan Healthcare Conference Presentation slide image

J.P. Morgan Healthcare Conference Presentation

Strongly focused on core therapy areas Developing pipeline through organic and business development progress GSK Infectious diseases Respiratory/ HIV Oncology immunology Arexvy MenABCWY Pneumococcal 24-valent mRNA Seasonal influenza/COVID-19 Shingrix GSK3943104 (Herpes simplex virus) GSK4348413 (gonorrhoea) gepotidacin Brexafemme Long-acting and ultra-long-acting N6LS (bNAb¹) 3rd generation INST12 Capsid inhibitor depemokimab camlipixant Nucala (COPD³) GSK4532990 (NASH4) GSK3858279 (osteoarthritis pain) GSK1070806 (atopic dermatitis) Jemperli Ojjaara Blenrep cobolimab CD226 axis tebipenem bepirovirsen Enabled by advanced technology and data platforms Note: select pipeline programmes shown 1. Broadly neutralising antibody 2. Integrase strand transfer inhibitor 3. Chronic obstructive pulmonary disease 4. Non-alcoholic steatohepatitis ST 5
View entire presentation